To evaluate if an intensive anticoagulation strategy using Edoxaban on top of standard of care (SOC) of COVID-19 therapy is superior to SOC (in-hospital moderate anticoagulation strategy = low-dose low-molecular weight heparin [LMWH] / Fondaparinux, ambulatory no anticoagulation, i.e. placebo within this trial) in reduction of morbidity and mortality end-points in patients with COVID-19
